Lisa Bollinger - 29 Jan 2026 Form 3 Insider Report for Polaryx Therapeutics, Inc. (PLYX)

Reporting relationship: Chief Medical Officer
Issuer ticker: PLYX
Reported as of: 29 Jan 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 29 Jan 2026, 16:43:49 UTC
Prior SEC filing: 20 Jun 2025
Next SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ G. Michael Landis, as attorney-in-fact for Lisa Bollinger

Key filing fact

Lisa Bollinger filed Form 3 for Polaryx Therapeutics, Inc. (PLYX) on 29 Jan 2026.

Key facts

This page summarizes Lisa Bollinger's Form 3 filing for Polaryx Therapeutics, Inc. (PLYX).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 29 Jan 2026, 16:43.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002024557 Primary reporting owner

Bollinger Lisa

Relationship: Chief Medical Officer
Address: SOUTH TOWER, 140 E RIDGEWOOD AVENUE,, SUITE 415, PARAMUS
Signature: /s/ G. Michael Landis, as attorney-in-fact for Lisa Bollinger
Signature date: 29 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PLYX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 150,358
Date: 29 Jan 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Includes 150,000 restricted stock units ("RSUs"), which will vest in four equal installments on November 15, 2026, November 15, 2027, November 15, 2028 and November 15, 2029, subject to the Reporting Person's continued service to the Issuer or its subsidiaries, Mstone Partners Healthcare Limited or its affiliates, or Curestone Partners Platform Limited or its affiliates. The RSUs are not deliverable unless and until the Issuer consummates a change in control within seven years of the grant date of such RSUs.

SEC remarks

Exhibit 24 - Power of Attorney